SCHEMBL2368680

SCHEMBL2368680

Cc1sc2ncnc(Cl)c2c1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.55
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPK1 P28482 2/20 0.54
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 1/20 0.53
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KDR P35968 4/20 0.52
CSNK2A2 P19784 3/20 0.52
CSNK2B P67870 3/20 0.52
CSNK2A1 P68400 3/20 0.52
NOD2 Q9HC29 1/20 0.49
KIT P10721 3/20 0.49
TEK Q02763 3/20 0.49
MAPT P10636 2/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369189 0.85 KDR (0.55) FGFR1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6666685 0.84 MAPT (0.56) FGFR1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL14965012 0.81 SMN1; SMN2 (0.42) FGFR1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL6665665 0.81 FGFR1 (0.62) FGFR1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL14013967 0.81 KDR (0.78) FGFR1L3MBTL1KDRKITTEK
SCHEMBL2368440 0.81 MCL1 (0.48) MEN1KMT2AKDRKITTEK
SCHEMBL26980589 0.81 MRGPRX1 (0.59) FGFR1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL2369505 0.78 ALDH1A1 (0.64) FGFR1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4765789 0.78 LIMK1 (0.68) FGFR1MEN1KMT2AMAPK1HPGD
SCHEMBL20513962 0.77 DHFR (0.39) FGFR1MEN1KMT2AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
CN-1823071-A Thienopyrimidine derivatives as potassium channel inhibitors XENTION DISCOVERY LTD (GB) 2006-08-23 CN disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed
US-20040138238-A1 Substituted aminopyrimidine compounds as neurokinin antagonists PREDIX PHARMACEUTICALS HOLDINGS, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 FGFR1 1333/4885MEN1 265/4885KMT2A 1857/4885
US-20040138238-A1 Substituted aminopyrimidine compounds as neurokinin antagonists TACR1, GRPR, BDKRB1 FGFR1 792/4885MEN1 2034/4885KMT2A 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.